logo

Redhill Biopharma Ltd. (RDHL)



Trade RDHL now with
  Date
  Headline
5/9/2022 8:37:34 AM RedHill Biopharma Announces $15 Mln Registered Direct Offering With Leading Healthcare Investor
3/17/2022 8:12:08 AM RedHill Biopharma Q4 Net Revenues $22.1 Mln Vs $21.6 Mln In Q3
12/6/2021 7:06:13 AM RedHill Biopharma: Opaganib Mechanism Not Impacted By Viral Spike-Protein Mutations, Including Omicron Mutations
11/30/2021 7:15:19 AM RedHill Biopharma Q3 Loss/shr $0.05 Same With Last Year
11/30/2021 7:03:35 AM RedHill Biopharma Q3 Net Loss $21.4 Mln; Net Revenues $21.6 Mln
11/8/2021 7:15:24 AM RedHill Biopharma Enters Strategic Agreement With Kukbo Co
10/12/2021 7:15:25 AM RedHill Biopharma Announces U.S. Patent Covering Talicia For H. Pylori Infection Through 2034
10/4/2021 8:08:36 AM RedHill ; Phase 2/3 Data Shows 62% Reduction In Mortality With Oral Opaganib In Moderately Severe COVID-19 Patients
9/23/2021 7:30:27 AM RedHill Biopharma Announces Settlement Of Movantik Patent Litigation With Aurobindo
9/13/2021 7:10:04 AM RedHill Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study Of Once-Daily Oral RHB-107 With South African Approval
9/7/2021 6:05:06 AM RedHill Biopharma Presents Three New Analyses Of Analyses Of Movantik Phase 3 Study Data At PAINWeek 2021
8/26/2021 7:28:45 AM RedHill Biopharma Q2 Loss/shr $0.06 Vs. Loss/shr $0.04 Last Year